New vaccine guidelines issued for the 2023-2024 flu season; USPSTF make recommendations on PrEP prescribing; maternal RSV vaccine; updated COVID vaccine shows strong immune response; new treatment approved for rare immune disease.

FDA issue recommendations to avoid Company's tests; RSV vaccine now available for older adults; New treatments approved for fibrodysplasia ossificans progressiva and for those with metastatic uveal melanoma with unresectable hepatic metastases; and gastrointestinal associations issue a statement regarding GLP-1 use prior to upper gastrointestinal endoscopy.

Oral postpartum depression treatment approved; generic naloxone nasal spray now available; weight management drug shows promise in reducing major cardiovascular events; CDC recommends routine use of RSV vaccine; social anxiety disorder spray shows potential.

Drug agencies issue letter addressing the prescription stimulant shortage; electronic transfer of controlled substances given green light; oral contraceptives recalled; expanded indication for Ebola vaccine; and a new over-the-counter opioid overdose treatment.

Single-use application to treat the molluscum contagiosum approved; Xdermvy has gotten the green light to treat demodex blepharitis; warfarin reversal treatment for use in urgent surgery; weight loss drug in short supply through 2023; cervical pessary assessed for reducing preterm birth.

Study supports the benefit of potential new Alzheimer drug; RSV treatment approved for neonates and infants; Veklury approval expanded; a blood test used to diagnose life-threatening heart muscle injuries has been recalled; Brenzavvy available for adults.

First over-the-counter birth control pill; expanded approval for Leqvio; Gavreto has an indication withdrawn; batches of Albuterol inhalers recalled; results from analysis of paclitaxel-coated devices.

New approvals for alopecia, generalized myasthenia gravis and type 1 diabetes; New colonoscopy prep option; And FDA denies application for pre-chirrotic fibrosis due to NASH.

FDA revoke Emergency Use Authorization for a COVID-19 vaccine; New approval for treatment of iron deficiency in patients with heart failure; Lumryz now available for excessive daytime sleepiness; Vowst approved for C. difficile infection; Prevymis approved for prophylaxis of CMV disease in adult kidney transplant recipients.

New vaccine for lower respiratory tract disease; A new treatment for heart failure; Concerns over some compounded semaglutide; New opioid use disorder treatment; Motion sickness Tx shows promise.